Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Glycogen storage disease type XII Indication Strategy Report 2026: ALDOA, Trials and Deals
Latest Hotspot
8 min read
Glycogen storage disease type XII Indication Strategy Report 2026: ALDOA, Trials and Deals
24 July 2026
2026 Glycogen storage disease type XII strategy: epidemiology, ALDOA biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Glycogen storage disease type XI Indication Strategy Report 2026: LDHA, Trials and Deals
Latest Hotspot
8 min read
Glycogen storage disease type XI Indication Strategy Report 2026: LDHA, Trials and Deals
24 July 2026
2026 Glycogen storage disease type XI strategy: epidemiology, LDHA biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Glycogen storage disease type VI Indication Strategy Report 2026: PYGL, Trials and Deals
Latest Hotspot
8 min read
Glycogen storage disease type VI Indication Strategy Report 2026: PYGL, Trials and Deals
24 July 2026
2026 Glycogen storage disease type VI strategy: epidemiology, PYGL biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Glycogen storage disease type 0 Indication Strategy Report 2026: GYS2, Trials and Deals
Latest Hotspot
8 min read
Glycogen storage disease type 0 Indication Strategy Report 2026: GYS2, Trials and Deals
24 July 2026
2026 Glycogen storage disease type 0 strategy: epidemiology, GYS2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Delusional disorder Indication Strategy Report 2026: D2 receptor, Trials and Deals
Latest Hotspot
8 min read
Delusional disorder Indication Strategy Report 2026: D2 receptor, Trials and Deals
24 July 2026
2026 Delusional disorder strategy: epidemiology, D2 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Schizoaffective disorder Indication Strategy Report 2026: D2 receptor, Trials and Deals
Latest Hotspot
8 min read
Schizoaffective disorder Indication Strategy Report 2026: D2 receptor, Trials and Deals
24 July 2026
2026 Schizoaffective disorder strategy: epidemiology, D2 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Seasonal affective disorder Indication Strategy Report 2026: SERT, Trials and Deals
Latest Hotspot
8 min read
Seasonal affective disorder Indication Strategy Report 2026: SERT, Trials and Deals
24 July 2026
2026 Seasonal affective disorder strategy: epidemiology, SERT biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Circadian rhythm sleep-wake disorder Indication Strategy Report 2026: Melatonin receptor, Trials and Deals
Latest Hotspot
8 min read
Circadian rhythm sleep-wake disorder Indication Strategy Report 2026: Melatonin receptor, Trials and Deals
24 July 2026
2026 Circadian rhythm sleep-wake disorder strategy: epidemiology, Melatonin receptor biology, clinical competition, recent deals, unmet need and market…
Read →
Kleine-Levin syndrome Indication Strategy Report 2026: Orexin receptor, Trials and Deals
Latest Hotspot
8 min read
Kleine-Levin syndrome Indication Strategy Report 2026: Orexin receptor, Trials and Deals
24 July 2026
2026 Kleine-Levin syndrome strategy: epidemiology, Orexin receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Chronic low back pain Indication Strategy Report 2026: NGF, Trials and Deals
Latest Hotspot
8 min read
Chronic low back pain Indication Strategy Report 2026: NGF, Trials and Deals
24 July 2026
2026 Chronic low back pain strategy: epidemiology, NGF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Read →
Fibromyalgia Indication Strategy Report 2026: Alpha2-delta calcium channel, Trials and Deals
Latest Hotspot
8 min read
Fibromyalgia Indication Strategy Report 2026: Alpha2-delta calcium channel, Trials and Deals
24 July 2026
2026 Fibromyalgia strategy: epidemiology, Alpha2-delta calcium channel biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
GRN-related frontotemporal dementia Indication Strategy Report 2026: Progranulin, Trials and Deals
Latest Hotspot
8 min read
GRN-related frontotemporal dementia Indication Strategy Report 2026: Progranulin, Trials and Deals
24 July 2026
2026 GRN-related frontotemporal dementia strategy: epidemiology, Progranulin biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →